BriaCell Therapeutics Corp BCTX 深 滬
已收盤 02-06 16:00:00 美东时间
4.18
+0.010
+0.24%
華盛通- 最 高4.235
- 今 開4.13
- 成交量 19.59万股
- 最 低 4.05
- 昨 收 4.17
- 總市值 2596.38万
- 52周最高 98.20
- 市盈率 靜 --
- 換手率 3.15%
- 52周最低 4.05
- 委 比 -1.84%
- 總股本 621.14万
- 歷史最高 1860.5799
- 量 比 0.97
- 振 幅 4.44%
- 歷史最低 4.05
- 每 手 1
- 風險率 14.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BriaCell Therapeutics Announces Data From Phase 2 Trial Evaluating Participants Surpassing Expected Benchmarks For Metastatic Breast Cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new
01-27 20:37
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp. announced positive Phase 2 survival data for patients with metastatic breast cancer treated with the Bria-IMT regimen. Nine of 25 patients treated since 2022 remain alive 18-47 months post-enrollment, exceeding benchmarks for standard therapies. No Bria-IMT-related discontinuations were reported, and the regimen continues under US FDA Fast Track Designation. These findings support the potential of Bria-IMT to significa...
01-27 12:30
Glaukos, Trip.com Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
01-14 21:05
What's Going On With BriaCell Therapeutics Stock Wednesday?
BriaCell Therapeutics stock surges with positive news of patient's complete resolution of lung metastasis in Bria-OTS study.
01-14 19:36
BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit
BriaCell Therapeutics (BCTX) priced a public offering of 5.37M units, with each unit consisting of one common share and one warrant. Each unit is being sold to the public at a price of $5.59 per unit ...
01-14 14:35
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
BriaCell Therapeutics Corp. has completed a public offering of 5,366,726 units at $5.59 per unit, raising approximately $30 million before fees. Each unit includes a common share or a pre-funded warrant and a warrant exercisable at $6.93 per share, expiring in five years. The warrants are listed on Nasdaq under "BCTXL." Proceeds will fund working capital, general corporate purposes, and business objectives. The offering closed on January 15, 2026...
01-14 02:00
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
Bria-OTS, a personalized off-the-shelf immunotherapy developed by BriaCell Therapeutics, has shown durable complete resolution of lung metastasis in a patient with metastatic breast cancer. After four doses of Bria-OTS monotherapy, the 78-year-old HR+, HER2-negative patient achieved 100% tumor resolution in the lung, confirmed at 4, 6, and 11 months. The patient remained stable at other sites with no treatment-limiting toxicities. The Phase 1/2a ...
01-13 12:30
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2...
01-07 23:32
BriaCell Therapeutics Publishes Phase 3 Bria-IMT Clinical Study In Metastatic Breast Cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its
2025-12-18 20:34
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Braze Inc (NYSE:BRZE) rose sharply in pre-market trading after the co...
2025-12-10 18:00
